Author
Listed:
- Matthias Gromeier
(Duke University Medical Center
The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center)
- Michael C. Brown
(Duke University Medical Center
The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center)
- Gao Zhang
(Duke University Medical Center
The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center)
- Xiang Lin
(Department of Computer Science at the New Jersey Institute of Technology)
- Yeqing Chen
(Department of Computer Science at the New Jersey Institute of Technology)
- Zhi Wei
(Department of Computer Science at the New Jersey Institute of Technology)
- Nike Beaubier
(Tempus Labs, Inc.)
- Hai Yan
(The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center
Duke University Medical Center)
- Yiping He
(The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center
Duke University Medical Center)
- Annick Desjardins
(Duke University Medical Center
The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center)
- James E. Herndon
(The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center
Duke University Medical Center)
- Frederick S. Varn
(The Jackson Laboratory for Genomic Medicine)
- Roel G. Verhaak
(The Jackson Laboratory for Genomic Medicine)
- Junfei Zhao
(Department of Systems Biology at Columbia University)
- Dani P. Bolognesi
(Duke University Medical Center
Istari Oncology Inc.)
- Allan H. Friedman
(Duke University Medical Center
The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center)
- Henry S. Friedman
(Duke University Medical Center
The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center)
- Frances McSherry
(Duke University Medical Center)
- Andrea M. Muscat
(Deakin University)
- Eric S. Lipp
(Duke University Medical Center
The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center)
- Smita K. Nair
(Duke University Medical Center)
- Mustafa Khasraw
(Duke University Medical Center
The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center)
- Katherine B. Peters
(Duke University Medical Center
The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center)
- Dina Randazzo
(Duke University Medical Center
The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center)
- John H. Sampson
(Duke University Medical Center
The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center)
- Roger E. McLendon
(The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center
Duke University Medical Center)
- Darell D. Bigner
(Duke University Medical Center
The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center)
- David M. Ashley
(Duke University Medical Center
The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center)
Abstract
Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term survival benefits in 10–20% of patients. Here we perform genomic analysis of tumor tissue from recurrent WHO grade IV glioblastoma patients acquired prior to immunotherapy intervention. We report that very low tumor mutation burden is associated with longer survival after recombinant polio virotherapy or after immune checkpoint blockade in recurrent glioblastoma patients. A relationship between tumor mutation burden and survival is not observed in cohorts of immunotherapy naïve newly diagnosed or recurrent glioblastoma patients. Transcriptomic analyses reveal an inverse relationship between tumor mutation burden and enrichment of inflammatory gene signatures in cohorts of recurrent, but not newly diagnosed glioblastoma tumors, implying that a relationship between tumor mutation burden and tumor-intrinsic inflammation evolves upon recurrence.
Suggested Citation
Matthias Gromeier & Michael C. Brown & Gao Zhang & Xiang Lin & Yeqing Chen & Zhi Wei & Nike Beaubier & Hai Yan & Yiping He & Annick Desjardins & James E. Herndon & Frederick S. Varn & Roel G. Verhaak , 2021.
"Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy,"
Nature Communications, Nature, vol. 12(1), pages 1-7, December.
Handle:
RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-020-20469-6
DOI: 10.1038/s41467-020-20469-6
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-020-20469-6. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.